Docetaxel and trastuzumab in the adjuvant setting : translating SABCS into clinical practiceEIERMANN, Wolfgang.European journal of cancer. Supplement (1990). 2006, Vol 4, Num 5, pp 5-9, issn 1359-6349, 5 p.Article

Response-Guided Neoadjuvant Chemotherapy for Breast CancerVON MINCKWITZ, Gunter; BLOHMER, Jens Uwe; JACKISCH, Christian et al.Journal of clinical oncology. 2013, Vol 31, Num 29, pp 3623-3630, issn 0732-183X, 8 p.Article

Alteration of Topoisomerase II―Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based ChemotherapyPRESS, Michael F; SAUTER, Guido; ROBERT, Nicholas et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 859-867, issn 0732-183X, 9 p.Article

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast : a randomized, controlled, open phase IIb studyVON MINCKWITZ, Gunter; COSTA, Serban D; EIERMANN, Wolfgang et al.Journal of clinical oncology. 2001, Vol 19, Num 15, pp 3506-3515, issn 0732-183XArticle

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH StudyPRAT, Aleix; BIANCHINI, Giampaolo; BYAKHOW, Mikhail et al.Clinical cancer research (Print). 2014, Vol 20, Num 2, pp 511-521, issn 1078-0432, 11 p.Article

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer GroupEIERMANN, Wolfgang; GRAF, Erika; KAUFMANN, Manfred et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 84-94, issn 0959-8049, 11 p.Article

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialVAIDYA, Jayant S; JOSEPH, David J; KESHTGAR, Mohammed et al.Lancet (British edition). 2010, Vol 376, Num 9735, pp 91-102, issn 0140-6736, 12 p.Article

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneBUZDAR, Aman U; ROBERTSON, John F. R; EIERMANN, Wolfgang et al.Cancer. 2002, Vol 95, Num 9, pp 2006-2016, issn 0008-543X, 11 p.Article

Adjuvant Trastuzumab in HER2-Positive Breast CancerSLAMON, Dennis; EIERMANN, Wolfgang; PINTER, Tamas et al.The New England journal of medicine. 2011, Vol 365, Num 14, pp 1273-1283, issn 0028-4793, 11 p.Article

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsVON MINCKWITZ, Gunter; UNTCH, Michael; MEHTA, Keyur et al.Breast cancer research and treatment. 2011, Vol 125, Num 1, pp 145-156, issn 0167-6806, 12 p.Article

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensVALERO, Vicente; FORBES, John; FUMOLEAU, Pierre et al.Journal of clinical oncology. 2011, Vol 29, Num 2, pp 149-156, issn 0732-183X, 8 p.Article

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast CancerGIANNI, Luca; BASELGA, José; BOZHOK, Alla et al.Journal of clinical oncology. 2009, Vol 27, Num 15, pp 2474-2481, issn 0732-183X, 8 p.Article

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyGIANNI, Luca; BASELGA, José; BOZHOK, Alla et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8715-8721, issn 1078-0432, 7 p., 1Article

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer PatientsHURVITZ, Sara A; BETTING, David J; DAMARAJU, Sambasivarao et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3478-3486, issn 1078-0432, 9 p.Article

Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsELLIS, Matthew J; YU TAO; EIERMANN, Wolfgang et al.Journal of the National Cancer Institute. 2008, Vol 100, Num 19, pp 1380-1388, issn 0027-8874, 9 p.Article

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer : A randomized trial (GABG-IV D-93)-The German adjuvant breast cancer groupKAUFMANN, Manfred; GRAF, Erika; SCHUMACHER, Martin et al.Journal of clinical oncology. 2005, Vol 23, Num 31, pp 7842-7848, issn 0732-183X, 7 p.Article

International expert panel on the use of Primary (preoperative) systemic treatment of operable breast cancer: Review and recommendationsKAUFMANN, Manfred; VON MINCKWITZ, Gunter; BLOHMER, Jens-Uwe et al.Journal of clinical oncology. 2003, Vol 21, Num 13, pp 2600-2608, issn 0732-183X, 9 p.Article

Pilot trial of Trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancerBIANCHI, Giulia; ALBANELL, John; GIANNI, Luca et al.Clinical cancer research. 2003, Vol 9, Num 16, pp 5944-5951, issn 1078-0432, 8 p., 1Article

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisCORTAZAR, Patricia; LIJUN ZHANG; SWAIN, Sandra M et al.Lancet (British edition). 2014, Vol 384, Num 9938, pp 164-172, issn 0140-6736, 9 p.Article

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialVAIDYA, Jayant S; WENZ, Frederik; EIERMANN, Wolfgang et al.Lancet (British edition). 2014, Vol 383, Num 9917, pp 603-613, issn 0140-6736, 11 p.Article

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast CancerVON MINCKWITZ, Gunter; SCHMITT, Wolfgang D; HILFRICH, Jörn et al.Clinical cancer research (Print). 2013, Vol 19, Num 16, pp 4521-4531, issn 1078-0432, 11 p.Article

FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast CancerBERGH, Jonas; JÖNSSON, Per-Ebbe; KERSTIN LIDBRINK, Elisabet et al.Journal of clinical oncology. 2012, Vol 30, Num 16, pp 1919-1925, issn 0732-183X, 7 p.Article

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortGIANNI, Luca; EIERMANN, Wolfgang; ANGEL CLIMENT, Miguel et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 377-384, issn 0140-6736, 8 p.Article

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer : An updateKAUFMANN, Manfred; HORTOBAGYI, Gabriel N; LEBEAU, Annette et al.Journal of clinical oncology. 2006, Vol 24, Num 12, pp 1940-1949, issn 0732-183X, 10 p.Article

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesVON MINCKWITZ, Gunter; UNTCH, Michael; JACKISCH, Christian et al.Journal of clinical oncology. 2012, Vol 30, Num 15, pp 1796-1804, issn 0732-183X, 9 p.Article